Patents Examined by Matthew Coughlin
  • Single-pot synthesis of dialkyl carbonates using catalyst from natural resource
    Patent number: 9611210
    Abstract: The present invention relates to a single-pot method for preparing dialkyl carbonates, the method comprises reaction of alkylene oxide with aliphatic or cyclic aliphatic alcohol, using wood ash catalyst, under CO2 pressure and heating the reaction mixture thereof to obtain dialkyl carbonates.
    Type: Grant
    Filed: January 12, 2015
    Date of Patent: April 4, 2017
    Assignee: INDIAN OIL CORPORATION LIMITED
    Inventors: Krishnarao Lopinti, Meeta Sharma, Ashok Kumar Tiwari, Ajay Kumar Arora, Suresh Kumar Puri, Anurag Ateet Gupta
  • Process for preparation of androgen receptor antagonist
    Patent number: 9611225
    Abstract: The present invention provides an isopropanol solvate of enzalutamide. The present invention also provides a process for the preparation of androgen receptor antagonist. In particular, the present invention provides a process for the preparation of enzalutamide or its pharmaceutically acceptable salts, hydrates, solvates, polymorphs or intermediates thereof.
    Type: Grant
    Filed: January 27, 2015
    Date of Patent: April 4, 2017
    Assignee: Cadila Healthcare Limited
    Inventors: Shri Prakash Dhar Dwivedi, Kumar Kamlesh Singh, Ganpat Dan Shimbhu Charan
  • Selective matrix metalloproteinase inhibitors
    Patent number: 9604957
    Abstract: The invention provides compounds, compositions, and methods for the treatment of diseases, disorders, or conditions that are modulated by matrix metalloproteinases (MMPs). The compounds can be selective MMP inhibitors, for example, selective inhibitors of MMP-2, MMP-9, and/or MMP-14. The disease, disorder, or condition can include, for example, stroke, neurological disorders, ophthalmological disorders, or wounds, such as chronic wounds or diabetic wounds.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: March 28, 2017
    Assignee: University of Notre Dame du Lac
    Inventors: Mayland Chang, Shahriar Mobashery
  • Sydnonimines-specific dopamine reuptake inhibitors and their use in treating dopamine related disorders
    Patent number: 9604945
    Abstract: Derivatives of Sydnonimine and its analogues, which bind selectively to dopamine transporter (DAT) proteins are useful for treating and delaying the progression of disorders and illnesses that are alleviated by inhibiting dopamine reuptake.
    Type: Grant
    Filed: March 27, 2013
    Date of Patent: March 28, 2017
    Assignee: Caliper Life Sciences, Inc.
    Inventors: Hao Chen, Ming Liu, Qi Su, Manish Raisinghani
  • Therapeutic compounds and methods
    Patent number: 9598441
    Abstract: The invention provides compounds of formula I: and salts thereof. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I and therapeutic methods for treating cancer using compounds of formula I.
    Type: Grant
    Filed: August 30, 2012
    Date of Patent: March 21, 2017
    Assignees: Wayne State University, Regents of the University of Michigan, Department of Veteran Affairs
    Inventors: Arun K. Rishi, Scott D. Larsen
  • Substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes useful for treating HCV infections
    Patent number: 9592222
    Abstract: The present disclosure provides substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes, of Formula I D-M-D??(Formula I) useful as antiviral agents. In certain embodiments disclosed herein M is a group —P-A-P— where A is Certain substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. Pharmaceutical compositions/and combinations containing one or more substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes and a pharmaceutically acceptable carrier are also provided by this disclosure. Methods for treating viral infections, including Hepatitis C viral infections are provided by the disclosure.
    Type: Grant
    Filed: September 20, 2016
    Date of Patent: March 14, 2017
    Assignee: ACHILLION PHARMACEUTICALS, INC.
    Inventors: Jason Allan Wiles, Qiuping Wang, Akihiro Hashimoto, Godwin Pais, Xiangzhu Wang, Venkat Gadhachanda, Avinash Phadke, Milind Deshpande, Dawei Chen
  • Modulators of C3a receptors
    Patent number: 9586914
    Abstract: Heterocyclic compounds that modulate C3a receptors and their use in the treatment or prevention of inflammatory diseases, infectious diseases, cancers, metabolic disorders, obesity, type 2 diabetes, metabolic syndrome and associated cardiovascular diseases are described. The use of the compounds in stimulating or suppressing an immune response is also described together with pharmaceutical compositions comprising the compounds or their pharmaceutically acceptable salts.
    Type: Grant
    Filed: November 7, 2012
    Date of Patent: March 7, 2017
    Assignee: THE UNIVERSITY OF QUEENSLAND
    Inventors: David Fairlie, Robert C. Reid
  • Isoquinoline and naphthyridine derivatives
    Patent number: 9586956
    Abstract: The invention provides novel compounds having the general formula: wherein A, R1 and R2 are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Grant
    Filed: July 31, 2014
    Date of Patent: March 7, 2017
    Assignee: Genentech, Inc.
    Inventors: Huifen Chen, Terry Crawford, Steven R. Magnuson, Chudi Ndubaku, Lan Wang
  • TRPM8 antagonists
    Patent number: 9585875
    Abstract: The invention relates to compounds acting as selective antagonists of Transient Receptor Potential cation channel subfamily M member 8 (TRPM8), and having formula (I). Said compounds are useful in the treatment of diseases associated with activity of TRPM8 such as pain, inflammation, ischaemia, neurodegeneration, stroke, psychiatric disorders, itch, irritable bowel diseases, cold induced and/or exhacerbated respiratory disorders and urological disorders.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: March 7, 2017
    Assignee: DOMPÉ FARMACEUTICI S.P.A.
    Inventors: Alessio Moriconi, Gianluca Bianchini, Sandro Colagioia, Laura Brandolini, Andrea Aramini, Chiara Liberati, Silvia Bovolenta
  • Substituted 2-(4-heterocyclylbenzyl)isoindolin-1-one analogs as positive allosteric modulators of the muscarinic acetylcholine receptor M1
    Patent number: 9586964
    Abstract: In one aspect, the invention relates to substituted 2-(4-heterocyclylbenzyl)isoindolin-1-one analogs compounds, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the muscarinic acetylcholine receptor M1 (mAChR M1); synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: October 28, 2012
    Date of Patent: March 7, 2017
    Assignee: Vanderbilt University
    Inventors: Craig W. Lindsley, P. Jeffrey Conn, Michael R. Wood, Corey R. Hopkins, Bruce J. Melancon, Michael S. Poslusney, Darren W. Engers
  • Synthetic process for aminocyclohexyl ether compounds
    Patent number: 9586899
    Abstract: Methods for the preparation of stereoisomerically substantially aminocyclohexyl ether compounds such as trans-(1R,2R)-aminocyclohexyl ether compounds and/or trans-(1S,2S)-aminocyclohexyl ether compounds as well as various intermediates and substrates are disclosed.
    Type: Grant
    Filed: August 4, 2015
    Date of Patent: March 7, 2017
    Assignee: Cardiome Pharma Corp.
    Inventors: Bertrand M. C. Plouvier, Doug Ta Hung Chou, Grace Jung, Lewis Siu Leung Choi, Tao Sheng, Anthony G. M. Barrett, Marco S. Passafaro, Martin Kurz, Daniel Moeckli, Pirmin Ulmann, Alfred Hedinger
  • Biaryl compositions and methods for modulating a kinase cascade
    Patent number: 9580387
    Abstract: The invention relates to compounds and methods for modulating one or more components of a kinase cascade.
    Type: Grant
    Filed: December 2, 2013
    Date of Patent: February 28, 2017
    Assignee: Athenex, Inc.
    Inventor: David G. Hangauer, Jr.
  • Methods of treatment using modulators of SIRT2
    Patent number: 9572789
    Abstract: The instant application describes novel compounds that modulate (in particular, inhibit) Sirt2, with structures according to Formulas (1) and (2) provided herein. The invention is also directed to pharmaceutical compositions thereof, methods of treatment (i.e., cancer and neurodegenerative disease) by administration of the modulating compounds, assay methods for finding modulators of Sirt2, and kits for practicing the assay method.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: February 21, 2017
    Assignee: CORNELL UNIVERSITY
    Inventors: Hening Lin, Bin He
  • Energetic N-substituted 3, 3-dinitroazetidine plasticizer and preparation method thereof
    Patent number: 9573894
    Abstract: N-substituted 3,3-dinitroazetidine, represented by the following Chemical Formula I, as an energetic plasticizer, and a method for preparing the same through a coupling reaction in which the energetic material 3,3-dinitroazetidine or an acid salt thereof serves as a nucleophile for the ?,?-unsaturated carbonyl compound as a substrate are provided. wherein R1 and R2 are each independently alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl, hydroxy, nitro, or a halogen atom, wherein the substituent of the substituted radicals is selected from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl, alkoxy, thioalkyl, amino, nitro, hydroxy, a halogen atom, and a combination thereof.
    Type: Grant
    Filed: September 3, 2015
    Date of Patent: February 21, 2017
    Assignee: AGENCY FOR DEFENSE DEVELOPMENT
    Inventors: Seung-Hee Kim, Jinseuk Kim, Chang-Woo Cho
  • Oxazolidinone antibacterial compound
    Patent number: 9573910
    Abstract: The invention relates to novel oxazolidinone compound. More particularly, the invention relates to novel [(S)—N-[[3-[4-fluoro-3-morpholino phenyl]-2-oxooxazolidin-5-yl] methyl] acetamide] compound of Formula-I which was disclosed in Indian Patent Application No. 5063/CHE/2013 and corresponding PCT/IN2014/000018. The compound is a broad spectrum antimicrobial agent effective against Multi-Drug Resistant S. Maltophilia pathogen and a large number of gram positive and gram negative pathogens. The compound has shown excellent biological activities against S. Maltophilia which has developed resistance against a large number of antibiotics including some of the known and widely used oxazolidinone derivatives.
    Type: Grant
    Filed: July 28, 2014
    Date of Patent: February 21, 2017
    Assignee: Lee Pharma Limited
    Inventors: Raghu Mitra Alla, Ajay Kumar Dubey, Srinivas Reddy Mallepalli, Ramakrishna Reddy Pongilati
  • Ionic liquids, the method for preparing the same and method for removing acetylenes from olefin mixtures using the ionic liquids
    Patent number: 9573915
    Abstract: There are provided an ionic liquid having ether group(s) in which a copper(I) compound is included, a method for preparing the same, and a method for removing traces amounts of acetylene-based hydrocarbon compounds included in olefin by absorption or extraction using the same. When the disclosed solution is used, oxidation of Cu(I) to Cu(II) is prevented since CuX is stabilized by the ionic liquid. Thus, selective removal efficiency of acetylenic compounds is improved greatly while the removal performance is retained for a long period of time. Further, since the solution according to the present disclosure is applicable as an extractant as well as an absorbent, the associated operation is simple and apparatus cost can be decreased.
    Type: Grant
    Filed: June 19, 2014
    Date of Patent: February 21, 2017
    Assignee: Kolon Industries, Inc.
    Inventors: Hyun Joo Lee, Byoung Sung Ahn, Hoon Sik Kim, Jin-Hyung Kim, Gyeong Taek Gong
  • Hexahydropentaleno derivatives, preparation method and use in medicine thereof
    Patent number: 9567300
    Abstract: The invention relates to hexahydropentaleno derivatives, the preparation method and use in medicine thereof, and in particular to hexahydropentaleno derivatives or stereo-isomers or pharmaceutically acceptable salts thereof as shown in general formula (I), and to the preparation method therefor and pharmaceutical compositions comprising the derivatives, and to the use thereof as a therapeutical agent, especially as a DPP-IV inhibitor. The definition of each substituent in formula (I) is the same as the definition in the description.
    Type: Grant
    Filed: June 25, 2013
    Date of Patent: February 14, 2017
    Assignee: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Zheng Gu, Guanpeng Qiu, Wuyong Wu, Panpan Kang, Zongyuan Zhang, Gang Chen, Chengsheng Lan, Yonggang Wei, Jiaping Wen, Guozhi Zhu, Yonghua Lu, Heran Wang, Yincai Wang, Mingyun Yuan, Kangzhi Ye, Guizhuan Su, PengCho Tang
  • Therapeutic compounds
    Patent number: 9561201
    Abstract: Substituted cinnamoyl anthranilate compounds exhibiting anti-fibrotic activity; or derivatives thereof, analogs thereof, pharmaceutically acceptable salts thereof, and metabolites thereof, with the proviso that the compound is no Tranilast.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: February 7, 2017
    Assignee: Fibrotech Therapeutics PTY LTD
    Inventors: Spencer John Williams, David Stapleton, Steven Zammit, Darren James Kelly, Richard Ernest Gilbert, Henry Krum
  • Compound for the treatment of hepatitis C
    Patent number: 9556162
    Abstract: The present invention provides (R)-5-(3-((2-(1,2,4-oxadiazol-3-yl)propan-2-yl)carbamoyl)phenyl)-6-(sec-butyl)-2-(4-fluorophenyl)-N-methylbenzofuran-3-carboxamide (formula I), including pharmaceutically acceptable salts, as well as compositions and methods of using the compound. The compound has activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
    Type: Grant
    Filed: December 8, 2014
    Date of Patent: January 31, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kap-Sun Yeung, Katharine A. Grant-Young
  • Functionnalized benzodithiophene polymers for electronic application
    Patent number: 9550791
    Abstract: The present invention relates to polymers comprising a repeating unit of the formula (I), and their use as organic semiconductor in organic electronic devices, especially in organic photovoltaics and photodiodes, or in a device containing a diode and/or an organic field effect transistor. The polymers according to the invention can have excellent solubility in organic solvents and excellent film-forming properties. In addition, high efficiency of energy conversion, excellent field-effect mobility, good on/off current ratios and/or excellent stability can be observed, when the polymers according to the invention are used in organic field effect transistors, organic photovoltaics (solar cells) and photodiodes.
    Type: Grant
    Filed: December 2, 2013
    Date of Patent: January 24, 2017
    Assignee: BASF SE
    Inventors: Matthias Welker, Mathieu G. R. Turbiez, Natalia Chebotareva, Hans Jürg Kirner